^
Association details:
| Biomarker: | EML4-ALK fusion + ALK-SSH2 fusion |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively
Published date:
02/10/2022
Excerpt:
The patient was a 38-year-old Chinese female without a history of smoking...coexistence of double ALK fusion: EML4-ALK (E6:A20, MAF = 24.7%) and ALK-SSH2 (A19:S3, MAF = 0.85%) (Fig. 2B), which was further validated by another NGS 10 cancer‐related gene panel (RNA-based detection for fusion genes, Amoy Diagnostics, Xiamen, China), EML4-ALK ALK-SSH2 (E6:A20, MAF = 25.6%; A19:S3, MAF = 0.68%, respectively) (Fig. 2 C). This patient was treated with crizotinib (250 mg twice daily) staring from December 31th, 2013. Chest CT scan after one-month treatment indicated a partial response (PR) to crizotinib (Fig. 1D).
DOI:
https://doi.org/10.1186/s13000-022-01212-9
